![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
A Malmberg, DM Jackson, A Eriksson and N Mohell
Department of Neuropharmacology, CNS Preclinical R & D, Astra Arcus AB, Sodertaje, Sweden.
In the present study we have compared the pharmacological properties of human dopamine (DA) D2A, D2B, and D3 receptors expressed in mammalian cell lines, using [3H]raclopride as a radioligand. Most of the compounds tested had about equal affinity for D2A and D3 receptors, with the exception of remoxipride, which displayed a 10-fold D2 selectivity, and the aminotetralin (+)-UH 232, which displayed a 5-fold D3 selectivity. Several antipsychotic agents, including clozapine and substituted benzamides, bound with 2-3-fold higher to the D2B (short) than to the D2A (long) isoform, whereas others failed to differentiate between the two isoforms. The atypical antipsychotic agent clozapine bound in a biphasic manner and with unexpectedly high affinity (35 nM) to the D2B receptor, suggesting that clozapine may not be as D4 selective as reported previously. In addition, remoxipride, a new antipsychotic agent with low potential to produce extrapyramidal side effects, displayed 2-3-fold higher affinity for the D2B receptor than for the D2A receptor. Furthermore, sodium differently regulated clozapine and benzamide binding to the various DA receptor subtypes. Thus, sodium decreased the affinity of clozapine for D2A and D2B receptors about 3-fold, whereas the affinity for D3 receptors was unaltered. In contrast, the affinity of raclopride for the three DA receptor subtypes was increased by sodium. Whether the unique characteristics of the binding of clozapine and benzamides to cloned DA receptors demonstrated in the present study are related to the favorable clinical properties of these compounds remains to be elucidated.
This article has been cited by other articles:
|
|
 |
|
  P. D. Shepard, C. C. Canavier, and E. S. Levitan Ether-a-go-go Related Gene Potassium Channels: What's All the Buzz About? Schizophr Bull, November 1, 2007; 33(6): 1263 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Renyi, J. L. Evenden, C. J. Fowler, E. Jerning, D. Kelder, D. Lake-Bakaar, L.-G. Larsson, N. Mohell, M. Sallemark, and S. B. Ross The Pharmacological Profile of (R)-3,4-Dihydro-N-isopropyl-3-(N-isopropyl-N-propylamino)-2H-1-benzopyran-5-carboxamide, a Selective 5-Hydroxytryptamine1A Receptor Agonist J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 883 - 893. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Talvik, A.-L. Nordstrom, S. Nyberg, H. Olsson, C. Halldin, and L. Farde No Support for Regional Selectivity in Clozapine-Treated Patients: A PET Study With [11C]Raclopride and [11C]FLB 457 Am J Psychiatry, June 1, 2001; 158(6): 926 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. G. Strange Antipsychotic Drugs: Importance of Dopamine Receptors for Mechanisms of Therapeutic Actions and Side Effects Pharmacol. Rev., March 1, 2001; 53(1): 119 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Piggott, E. F. Marshall, N. Thomas, S. Lloyd, J. A. Court, E. Jaros, D. Burn, M. Johnson, R. H. Perry, I. G. McKeith, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution Brain, August 1, 1999; 122(8): 1449 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Schetz, A. Chu, and D. R. Sibley Zinc Modulates Antagonist Interactions with D2-Like Dopamine Receptors through Distinct Molecular Mechanisms J. Pharmacol. Exp. Ther., May 1, 1999; 289(2): 956 - 964. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Millan, A. Newman-Tancredi, M. Brocco, A. Gobert, F. Lejeune, V. Audinot, J.-M. Rivet, R. Schreiber, A. Dekeyne, M. Spedding, et al. S 18126 ({2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl}), a Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An In Vitro and In Vivo Comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and Raclopride J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 167 - 186. [Abstract] [Full Text]
|
|
|
|
|
|
A. Malmberg, A. Mikaels, and N. Mohell Agonist and Inverse Agonist Activity at the Dopamine D3 Receptor Measured by Guanosine 5'-[gamma -Thio]Triphosphate-[35S] Binding J. Pharmacol. Exp. Ther., April 1, 1998; 285(1): 119 - 126. [Abstract] [Full Text]
|
|
|
|
 |
|
 A.-L. Nordstrom, S. Nyberg, H. Olsson, L. Farde, and P. Seeman Positron Emission Tomography Finding of a High Striatal D2Receptor Occupancy in Olanzapine-Treated Patients Arch Gen Psychiatry, March 1, 1998; 55(3): 283 - 284. [Full Text] [PDF]
|
|
|
|
 |
|
 C. MISSALE, S. R. NASH, S. W. ROBINSON, M. JABER, and M. G. CARON Dopamine Receptors: From Structure to Function Physiol Rev, January 1, 1998; 78(1): 189 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ahlenius, E. Ericson, V. Hillegaart, L. B. Nilsson, P. Salmi, and A. Wijkström In Vivo Effects of Remoxipride and Aromatic Ring Metabolites in the Rat J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1356 - 1366. [Abstract] [Full Text]
|
|
|
|
|
|
M. S. Lidow and P. S. Goldman-Rakic Differential Regulation of D2 and D4 Dopamine Receptor mRNAs in the Primate Cerebral Cortex vs. Neostriatum: Effects of Chronic Treatment with Typical and Atypical Antipsychotic Drugs J. Pharmacol. Exp. Ther., November 1, 1997; 283(2): 939 - 946. [Abstract] [Full Text]
|
|
|
|
|
|
L. Johansson, D. Sohn, S.-O. Thorberg, D. M. Jackson, D. Kelder, L.-G. Larsson, L. Rényi, S. B. Ross, C. Wallsten, H. Eriksson, et al. The Pharmacological Characterization of a Novel Selective 5-Hydroxytryptamine1A Receptor Antagonist, NAD-299 J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 216 - 225. [Abstract] [Full Text]
|
|
|
|
|
|
B. Levant The D3 Dopamine Receptor: Neurobiology and Potential Clinical Relevance Pharmacol. Rev., September 1, 1997; 49(3): 231 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Schoemaker, Y. Claustre, D. Fage, L. Rouquier, K. Chergui, O. Curet, A. Oblin, F. Gonon, C. Carter, J. Benavides, et al. Neurochemical Characteristics of Amisulpride, an Atypical Dopamine D2/D3 Receptor Antagonist with Both Presynaptic and Limbic Selectivity J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 83 - 97. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. Armstrong and P. G. Strange Dopamine D2 Receptor Dimer Formation. EVIDENCE FROM LIGAND BINDING J. Biol. Chem., June 15, 2001; 276(25): 22621 - 22629. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
